Oligodendrocyte progenitor cell compositions
AssigneeAsterias Biotherapeutics, Inc.
InventorsErik Michael Whiteley, Uzma Shoukat-Mumtaz, Rashi Srivastava, Nathan Charles Manley, Casey Christopher Case
Life of this patent
Estimating the term…
Loading patent…
AssigneeAsterias Biotherapeutics, Inc.
InventorsErik Michael Whiteley, Uzma Shoukat-Mumtaz, Rashi Srivastava, Nathan Charles Manley, Casey Christopher Case
Estimating the term…
Compositions comprising a population of oligodendrocyte progenitor cells (OPCs), as well as methods of making and using the same, are provided. In one aspect, a container comprising a composition, where the composition comprises a population of cells comprising a plurality of OPCs, and where the population of cells comprises less than 15% undesirable cell types is provided. In another aspect, the population of cells comprises less than 15% undesirable epithelial lineage cells. In yet another aspect, the population of cells comprises less than 2% K7 positive cells. In an aspect, a population of cells comprising a plurality of oligodendrocyte progenitor cells is capable of forming less than one epithelial cyst per 100,000 cells in a cyst assay is provided. An even further aspect of the present disclosure is a container comprising a composition, where the composition comprising a plurality of oligodendrocyte progenitor cells is useful in treating treat stroke, spinal cord injury, and multiple sclerosis.
A container comprising a pharmaceutical composition comprising a population of cells comprising a plurality of oligodendrocyte progenitor cells (OPCs), wherein:
Dependencies are inferred from the claim text.